Resistance in mBC

Treatment resistance to current therapies remains an issue for patients with metastatic breast cancer (mBC)3-5

When the interval between treatment and recurrence is brief, treatment resistance is the likely cause3

  • Due to the use of anthracyclines and taxanes in the adjuvant setting, the emergence of resistance may limit their use in the metastatic setting3,5,6

Some common causes of resistance to taxanes and other chemotherapies5

Defined resistance criteria used in IXEMPRA® (ixabepilone) registrational studies1

HER2, human epidermal growth factor receptor 2.
* For anthracyclines, patients who received a minimum cumulative dose of 240 mg/m2 of doxorubicin or 360 mg/m2 of epirubicin were also eligible.

References: 1. IXEMPRA (ixabepilone) Prescribing Information; January 2016. 2. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8(8):2086-2095. 3. Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer. 2013;2013:137414. doi:10.1155/2013/137414. 4. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275-292. 5. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34(4):378-390. doi:10.1016/j.ctrv.2008.01.007.

Indications and Important Safety Informationexpand

Important Safety Information
WARNING: Toxicity in hepatic impairment


Peripheral neuropathy


Hypersensitivity reaction


Cardiac adverse reactions

Potential for cognitive impairment from excipients

Adverse reactions


Combination with capecitabine

Cremophor is a registered trademark of BASF AG.

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; CTC = common terminology criteria.


IXEMPRA® (ixabepilone) is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

  • Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting
  • Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting

IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

Please see US Full Prescribing Information, including boxed WARNING regarding hepatic impairment.

Medical information

For product information or to report an adverse reaction, please call 1-844-586-8953 or e-mail

This site is intended for US healthcare professionals.

The R-Pharm US Access and Support logo is a trademark and IXEMPRA® is a registered trademark of R-Pharm US Operating LLC, a wholly owned subsidiary of R-Pharm US LLC.

© 2021, R-PHARM US. All rights reserved. IXE-00096-02   08/16

Please verify if you are a US healthcare professional